171 related articles for article (PubMed ID: 37373887)
1. Correlation Studies between S100 Protein Level and Soluble MIA or Tissue MelanA and gp100 (HMB45) Expression in Cutaneous Melanoma.
Bolovan LM; Ceausu M; Stanciu AE; Panait ME; Busca A; Hotnog CM; Bleotu C; Gales LN; Georgescu MT; Prunoiu VM; Brasoveanu LI; Voinea SC
J Pers Med; 2023 May; 13(6):. PubMed ID: 37373887
[TBL] [Abstract][Full Text] [Related]
2. Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA.
Sundram U; Harvell JD; Rouse RV; Natkunam Y
Mod Pathol; 2003 Aug; 16(8):802-10. PubMed ID: 12920225
[TBL] [Abstract][Full Text] [Related]
3. Expression of HMB45, MelanA and SOX10 is rare in non-small cell lung cancer.
Kriegsmann M; Kriegsmann K; Harms A; Longuespée R; Zgorzelski C; Leichsenring J; Muley T; Winter H; Kazdal D; Goeppert B; Warth A
Diagn Pathol; 2018 Sep; 13(1):68. PubMed ID: 30205833
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma.
Garnier JP; Letellier S; Cassinat B; Lebbé C; Kerob D; Baccard M; Morel P; Basset-Seguin N; Dubertret L; Bousquet B; Stoitchkov K; Le Bricon T
Eur J Cancer; 2007 Mar; 43(4):816-21. PubMed ID: 17276671
[TBL] [Abstract][Full Text] [Related]
5. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients.
Schmitz C; Brenner W; Henze E; Christophers E; Hauschild A
Anticancer Res; 2000; 20(6D):5059-63. PubMed ID: 11326668
[TBL] [Abstract][Full Text] [Related]
6. Circulating melanoma exosomes as diagnostic and prognosis biomarkers.
Alegre E; Zubiri L; Perez-Gracia JL; González-Cao M; Soria L; Martín-Algarra S; González A
Clin Chim Acta; 2016 Feb; 454():28-32. PubMed ID: 26724367
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta.
Juergensen A; Holzapfel U; Hein R; Stolz W; Buettner R; Bosserhoff A
Tumour Biol; 2001; 22(1):54-8. PubMed ID: 11054027
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo.
Cormier JN; Hijazi YM; Abati A; Fetsch P; Bettinotti M; Steinberg SM; Rosenberg SA; Marincola FM
Int J Cancer; 1998 Feb; 75(4):517-24. PubMed ID: 9466650
[TBL] [Abstract][Full Text] [Related]
9. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical characterization of benign activation of junctional melanocytes and melanoma in situ of the nail unit.
Chu A; André J; Rich P; Leachman S; Thompson CT
J Cutan Pathol; 2019 Jul; 46(7):479-483. PubMed ID: 30887559
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of [18F]-fluoro-deoxy-glucose PET/CT, S100 or MIA for assessment of cancer-associated mortality in patients with high risk melanoma.
Essler M; Link A; Belloni B; Mirceva V; Souvatzoglou M; Thaler M; Haller B; Hein R; Krause BJ
PLoS One; 2011; 6(9):e24632. PubMed ID: 21935432
[TBL] [Abstract][Full Text] [Related]
12. Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.
Rothberg BE; Moeder CB; Kluger H; Halaban R; Elder DE; Murphy GF; Lazar A; Prieto V; Duncan LM; Rimm DL
Mod Pathol; 2008 Sep; 21(9):1121-9. PubMed ID: 18552823
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
14. Expression of melanoma inhibitory activity in melanoma and nonmelanoma tissue specimens.
Perez RP; Zhang P; Bosserhoff AK; Buettner R; Abu-Hadid M
Hum Pathol; 2000 Nov; 31(11):1381-8. PubMed ID: 11112213
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma.
Tas F; Yasasever V; Duranyildiz D; Camlica H; Ustuner Z; Aydiner A; Topuz E
Am J Clin Oncol; 2004 Jun; 27(3):225-8. PubMed ID: 15170138
[TBL] [Abstract][Full Text] [Related]
16. The correlation of TRPM1 (Melastatin) mRNA expression with microphthalmia-associated transcription factor (MITF) and other melanogenesis-related proteins in normal and pathological skin, hair follicles and melanocytic nevi.
Lu S; Slominski A; Yang SE; Sheehan C; Ross J; Carlson JA
J Cutan Pathol; 2010 Apr; 37 Suppl 1(Suppl 1):26-40. PubMed ID: 20482673
[TBL] [Abstract][Full Text] [Related]
17. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
[TBL] [Abstract][Full Text] [Related]
18. A Comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients.
Faries MB; Gupta RK; Ye X; Lee C; Yee R; Leopoldo Z; Essner R; Foshag LJ; Elashoff D; Morton DL
Cancer Invest; 2007 Aug; 25(5):285-93. PubMed ID: 17661202
[TBL] [Abstract][Full Text] [Related]
19. [Protein S100 beta and Melanoma Inhibitory Activity (MIA): a prospective study of their clinical value for the early detection of metastasis in malignant melanoma].
Loppin M; Quillien V; Adamski H; Ollivier I; Garlantézec R; Chevrant-Breton J
Ann Dermatol Venereol; 2007; 134(6-7):535-40. PubMed ID: 17657179
[TBL] [Abstract][Full Text] [Related]
20. Threshold Optimization for Tumor Markers S100b and MIA in Uveal Melanoma - A Single Center Analysis.
Glaser N; Petzold A; Wessely A; Kaufmann MD; Koch EAT; Knorr H; Voskens C; Heppt MV; Berking C; Erdmann M
Anticancer Res; 2023 Oct; 43(10):4525-4532. PubMed ID: 37772590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
